Unaudited NAV and Notice of Financial Results (1339853)
April 29 2022 - 5:44AM
UK Regulatory
Arix Bioscience PLC (ARIX) Unaudited NAV and Notice of Financial
Results 29-Apr-2022 / 10:44 GMT/BST Dissemination of a Regulatory
Announcement, transmitted by EQS Group. The issuer is solely
responsible for the content of this announcement.
-----------------------------------------------------------------------------------------------------------------------
PRESS RELEASE
Arix Bioscience plc
Unaudited NAV and Notice of Financial Results
LONDON, 29 April 2022: Arix Bioscience plc ("Arix" or the
"Company") (LSE: ARIX), a global venture capital company focused on
investing in breakthrough biotechnology companies, announces the
unaudited NAV of the Company as follows:
NAV Breakdown
Date Total NAV
Listed Portfolio Unlisted Portfolio Cash Other Interests NAV per share
31-Dec-21 GBP63.3m GBP54.6m GBP134.2m GBP3.3m GBP255.4m
GBP1.98
31-Mar-22 GBP53.5m GBP57.2m GBP127.8m GBP2.8m GBP241.3m
GBP1.87
In line with the reconstituted Board's desire to improve
corporate governance and transparency, and with the current balance
of public companies within the portfolio, Arix intends to provide
regular market updates on its unaudited NAV and is therefore today
also releasing its position as of 31 March 2022.
Arix will announce its results for the full year ended 31
December 2021, on 5 May 2022 utilising the FCA's temporary relief
from reporting deadlines due to the impact of the Covid-19
pandemic. The Board does not expect any material changes to the NAV
for the year ended 31 December 2021 on publication of the audited
financial results.
The Company will also host a virtual analyst presentation
followed by a Q&A session at 12pm GMT on 5 May. Analysts and
investors who wish to participate should visit this link to
register.
The webcast of the presentation will be available on the
Investor Relations section of the Company's website at
https://arixbioscience.com/investor-relations/events-presentations
For any details of the webcast or conference call please
contact: arix@powerscourt-group.com
[ENDS]
Enquiries
For more information on Arix, please contact:
Arix Bioscience plc
+44 (0)20 7290 1050
ir@arixbioscience.com
Powerscourt Group
Sarah MacLeod, Ibrahim Khalil
+44 (0)20 7250 1446
arix@powerscourt-group.com
About Arix Bioscience plc
Arix Bioscience plc is a global venture capital company focused
on investing in breakthrough biotech companies around cutting-edge
advances in life sciences.
We collaborate with exceptional entrepreneurs and provide the
capital, expertise and global networks to help accelerate their
ideas into important new treatments for patients. As a listed
company, we are able to bring this exciting growth phase of our
industry to a broader range of investors.
www.arixbioscience.com
-----------------------------------------------------------------------------------------------------------------------
ISIN: GB00BD045071
Category Code: NOR
TIDM: ARIX
LEI Code: 213800OVT3AHQCXNIX43
OAM Categories: 3.1. Additional regulated information required to be disclosed under the laws of a Member State
Sequence No.: 158688
EQS News ID: 1339853
End of Announcement EQS News Service
=------------------------------------------------------------------------------------
Image link:
https://eqs-cockpit.com/cgi-bin/fncls.ssp?fn=show_t_gif&application_id=1339853&application_name=news
(END) Dow Jones Newswires
April 29, 2022 05:44 ET (09:44 GMT)
Arix Bioscience (LSE:ARIX)
Historical Stock Chart
From Mar 2024 to Apr 2024
Arix Bioscience (LSE:ARIX)
Historical Stock Chart
From Apr 2023 to Apr 2024